Research programme: FGF-2 cancer vaccine - EntreMed

Drug Profile

Research programme: FGF-2 cancer vaccine - EntreMed

Alternative Names: ENMD-0996

Latest Information Update: 19 Dec 2008

Price : $50

At a glance

  • Originator EntreMed
  • Class Cancer vaccines
  • Mechanism of Action Angiogenesis inhibitors; Fibroblast growth factor inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 19 Dec 2008 Discontinued - Preclinical for Cancer in USA (Parenteral)
  • 21 Jul 2006 This programme is still in active development
  • 16 Feb 2005 Preclinical data from a media release have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top